Levetiracetam reduces myoclonus in corticobasal degeneration: Report of two cases

Tibor Kovács, Marianna Farsang, Edina Vitaszil, Péter Barsi, Tamás Györke, Imre Szirmai, Anita Kamondi

Research output: Article

9 Citations (Scopus)


Levetiracetam (LEV) has been shown to suppress myoclonus of various origins. Corticobasal degeneration (CBD), a progressive neurodegenerative disorder with Parkinsonian syndrome, is frequently accompanied by myoclonus. We investigated the effect of LEV on myoclonus in two CBD patients. LEV remarkably decreased the myoclonic activity in both patients already at 1,500 mg/day dose. This is the first report on LEV alleviating myoclonus in CBD. Our data indicate that it might be worthwhile to assess this effect in an appropriately designed study.

Original languageEnglish
Pages (from-to)1631-1634
Number of pages4
JournalJournal of neural transmission
Issue number12
Publication statusPublished - jan. 1 2009

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health
  • Biological Psychiatry

Fingerprint Dive into the research topics of 'Levetiracetam reduces myoclonus in corticobasal degeneration: Report of two cases'. Together they form a unique fingerprint.

  • Cite this